Business
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical
About this update from Bioage Labs, Inc.
[{"type":"image","alt":"BioAge Labs, Inc.","displaySize":"","headline":null,"caption":"BioAge Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BVCyonVYcqJQSCUAhAU_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/612cb01db2ea44f61d54947f4e4723e0","width":300,"height":300}},"lazy":false},{"type":"text","content":"Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET","length":61,"tagName":"p"},{"type":"text","content":"Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease","length":168,"tagName":"p"},{"type":"text","content":"Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session","length":136,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that it will host an R&D Day webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.","length":376,"tagName":"p"},{"type":"text","content":"The event will focus on BGE-102, the Company's potent, structurally novel, orally available NLRP3 inflammasome inhibitor with potential best-in-class attributes. Members of BioAge's leadership team will present Phase 1 clinical data and the therapeutic rationale for advancing BGE-102 in atherosclerotic cardiovascular disease (ASCVD) and retinal disease, two indication areas in which NLRP3-driven inflammation is implicated in disease pathology.","length":455,"tagName":"p"},{"type":"text","content":"BioAge management will be joined by four leading academic and clinical experts, who will share their perspectives on NLRP3 biology and the diseases BGE-102 is being developed to treat:","length":184,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Michael Davidson, MD — Professor and Director of the Lipid Clinic at the University of Chicago Pritzker S...